

Felix Kh Chun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1670696/publications.pdf>

Version: 2024-02-01

177
papers

9,542
citations

25034
57
h-index

45317
90
g-index

191
all docs

191
docs citations

191
times ranked

7397
citing authors

#	ARTICLE	IF	CITATIONS
1	Super early detailed assessment of lower urinary tract symptoms after holmium laser enucleation of the prostate (HoLEP): a prospective study. <i>World Journal of Urology</i> , 2020, 38, 3207-3217.	2.2	7
2	Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection. <i>World Journal of Men's Health</i> , 2020, 38, 32.	3.3	2
3	Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes. <i>Urologia Internationalis</i> , 2019, 102, 51-59.	1.3	4
4	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 81.e17-81.e24.	1.6	18
5	North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. <i>Prostate</i> , 2017, 77, 542-548.	2.3	15
6	Local Therapy Improves Survival in Metastatic Prostate Cancer. <i>European Urology</i> , 2017, 72, 118-124.	1.9	100
7	Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. <i>Prostate</i> , 2017, 77, 105-113.	2.3	21
8	Wound dehiscence in a sample of 1,776 cystectomies: identification of predictors and implications for outcomes. <i>BJU International</i> , 2016, 117, E95-E101.	2.5	23
9	Thermal Ablation of Renal Tumors. <i>Deutsches Arzteblatt International</i> , 2015, 112, 412-8.	0.9	23
10	Natural history of surgically treated high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 163.e7-163.e13.	1.6	101
11	Evidence from the "PROspective Multicenter Radical Cystectomy Series 2011 (PROMETRICS 2011)" Study: How are Preoperative Patient Characteristics Associated with Urinary Diversion Type After Radical Cystectomy for Bladder Cancer?. <i>Annals of Surgical Oncology</i> , 2015, 22, 1032-1042.	1.5	33
12	The Impact of Resident Involvement in Male One-stage Anterior Urethroplasties. <i>Urology</i> , 2015, 85, 937-941.	1.0	21
13	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. <i>Journal of Surgical Education</i> , 2015, 72, 1018-1025.	2.5	36
14	Prognostic impact of infiltration of the vagina and/or uterus in women undergoing anterior pelvic exenteration for urothelial carcinoma of the bladder: results of a contemporary multicentre series. <i>World Journal of Urology</i> , 2015, 33, 343-350.	2.2	4
15	In Reply. <i>Deutsches Arzteblatt International</i> , 2015, 112, 758.	0.9	0
16	Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. <i>Canadian Urological Association Journal</i> , 2014, 8, 75.	0.6	11
17	Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. <i>British Journal of Cancer</i> , 2014, 111, 213-219.	6.4	24
18	Prognosis of patients with pelvic lymph node (<sc>LN</sc>) metastasis after radical prostatectomy: Value of extranodal extension and size of the largest <sc>LN</sc> metastasis. <i>BJU International</i> , 2014, 114, 503-510.	2.5	33

#	ARTICLE	IF	CITATIONS
19	MALDI imaging-based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays. These authors contributed equally to this work. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1225-1233.	1.6	27
20	Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1259-1266.	1.6	50
21	MDCT for evaluation of urolithiasis: Iterative reconstruction allows for a significant reduction of the applied radiation dose while maintaining high subjective and objective image quality. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 283-290.	1.8	14
22	Predictors of survival in patients with disease recurrence after radical nephroureterectomy. BJU International, 2014, 113, 911-917.	2.5	28
23	Prediction of metastatic status in non-seminomatous testicular cancer. World Journal of Urology, 2014, 32, 1205-1211.	2.2	6
24	Holmium Laser Enucleation of the Prostate Is Safe in Patients with Prostate Cancer and Lower Urinary Tract Symptoms: A Retrospective Feasibility Study. Journal of Endourology, 2014, 28, 335-341.	2.1	16
25	Prostate imaging: the future is now: current concepts and future potentials. World Journal of Urology, 2014, 32, 843-845.	2.2	2
26	A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center. World Journal of Urology, 2014, 32, 891-897.	2.2	7
27	Concomitant Seminal Vesicle Invasion in pT4a Urothelial Carcinoma of the Bladder with Contiguous Prostatic Infiltration is an Adverse Prognosticator for Cancer-Specific Survival after Radical Cystectomy. Annals of Surgical Oncology, 2014, 21, 4034-4040.	1.5	13
28	Reduced membranous MET expression is linked to bladder cancer progression. Cancer Genetics, 2014, 207, 147-152.	0.4	5
29	Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. European Urology, 2014, 66, 439-446.	1.9	24
30	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 47.e1-47.e8.	1.6	8
31	Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. European Urology, 2014, 66, 156-163.	1.9	156
32	The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: Which markers matter and how should they be used?. World Journal of Urology, 2014, 32, 871-880.	2.2	8
33	Impact of Preoperative Anemia on Oncologic Outcomes of Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. Journal of Urology, 2014, 191, 316-322.	0.4	49
34	External validation of the updated briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. Prostate, 2013, 73, 211-218.	2.3	51
35	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. BJU International, 2013, 111, 74-84.	2.5	26
36	Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU International, 2013, 111, 404-411.	2.5	48

#	ARTICLE	IF	CITATIONS
37	Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World Journal of Urology, 2013, 31, 1029-1036.	2.2	55
38	Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. World Journal of Urology, 2013, 31, 847-853.	2.2	13
39	Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. International Urology and Nephrology, 2013, 45, 1561-1567.	1.4	13
40	Reply. BJU International, 2013, 111, E20-1.	2.5	2
41	Impact of Age and Comorbidities on Long-term Survival of Patients with High-risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Competing-risks Analysis. European Urology, 2013, 63, 693-701.	1.9	98
42	Assays for Prostate Cancer. Molecular Diagnosis and Therapy, 2013, 17, 1-8.	3.8	6
43	Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. International Journal of Cancer, 2013, 132, 2948-2955.	5.1	25
44	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. European Urology, 2013, 63, 371-378.	1.9	47
45	Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. European Urology, 2013, 63, 201-209.	1.9	114
46	Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU International, 2013, 111, E30-6.	2.5	77
47	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. European Urology, 2013, 63, 1082-1090.	1.9	98
48	Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1716-1724.	1.6	15
49	The Search for Biomarkers of Metastatic Seminoma. Journal of Urology, 2013, 190, 1046-1051.	0.4	9
50	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. European Urology, 2013, 64, 456-464.	1.9	101
51	Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Non-muscle-invasive Bladder Cancer. European Urology, 2013, 63, 724-732.	1.9	105
52	Obesity is Associated with Worse Outcomes in Patients with T1 High Grade Urothelial Carcinoma of the Bladder. Journal of Urology, 2013, 190, 480-486.	0.4	66
53	Impact of Clinical and Histopathological Parameters on Disease Specific Survival in Patients with Collecting Duct Renal Cell Carcinoma: Development of a Disease Specific Risk Model. Journal of Urology, 2013, 190, 458-463.	0.4	31
54	The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guérin Instillation Therapy on the Quality of Life in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Prospective, Randomized, Phase II Trial. Journal of Urology, 2013, 190, 857-862.	0.4	58

#	ARTICLE	IF	CITATIONS
55	<i>PTEN</i> deletions are related to disease progression and unfavourable prognosis in early bladder cancer. <i>Histopathology</i> , 2013, 63, 670-677.	2.9	30
56	Prediction of the Risk of Harboring Prostate Cancer by a Prebiopsy Nomogram Based on Extended Biopsy Protocol. <i>Urologia Internationalis</i> , 2013, 90, 306-311.	1.3	4
57	Short-Term Outcome and Morbidity of Different Contemporary Urethroplasty Techniques—A Preliminary Comparison. <i>Journal of Endourology</i> , 2013, 27, 925-929.	2.1	19
58	The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy. <i>Biomarkers in Medicine</i> , 2013, 7, 843-850.	1.4	5
59	Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. <i>BJU International</i> , 2013, 112, 623-637.	2.5	31
60	Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml. <i>PLoS ONE</i> , 2013, 8, e67687.	2.5	87
61	Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer. <i>Pathology</i> , 2012, 44, 448-452.	0.6	11
62	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. <i>World Journal of Urology</i> , 2012, 30, 807-814.	2.2	16
63	Transurethral Holmium Laser Enucleation Versus Transurethral Resection of the Prostate and Simple Open Prostatectomy—Which Procedure is Faster?. <i>Journal of Urology</i> , 2012, 187, 1608-1613.	0.4	51
64	Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2012, 188, 2120-2128.	0.4	45
65	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. <i>Annals of Surgical Oncology</i> , 2012, 19, 4337-4344.	1.5	53
66	Head to Head Comparison of Nomograms Predicting Probability of Lymph Node Invasion of Prostate Cancer in Patients Undergoing Extended Pelvic Lymph Node Dissection. <i>Urology</i> , 2012, 79, 546-551.	1.0	34
67	Assessment of Cancer Control Outcomes in Patients With High-risk Renal Cell Carcinoma Treated With Partial Nephrectomy. <i>Urology</i> , 2012, 80, 347-353.	1.0	49
68	Protocol-based Active Surveillance for Low-risk Prostate Cancer: Anxiety Levels in Both Men and Their Partners. <i>Urology</i> , 2012, 80, 564-569.	1.0	26
69	Predicting the risk of lymph node invasion during radical prostatectomy using the European association of urology guideline nomogram: A validation study. <i>European Journal of Surgical Oncology</i> , 2012, 38, 624-629.	1.0	6
70	Inflammatory prognostic markers in clear cell renal cell carcinoma—preoperative C-reactive protein does not improve predictive accuracy. <i>BJU International</i> , 2012, 110, E771-7.	2.5	17
71	Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2012, 188, 398-404.	0.4	114
72	National Trends and Disparities in the Use of Minimally Invasive Adult Pyeloplasty. <i>Journal of Urology</i> , 2012, 188, 913-918.	0.4	44

#	ARTICLE	IF	CITATIONS
73	Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes. <i>Current Urology Reports</i> , 2012, 13, 122-135.	2.2	51
74	Does Low-Risk Prostate Cancer Detection Change With Repeat Biopsies?. <i>European Urology</i> , 2012, 61, 230-231.	1.9	1
75	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. <i>European Urology</i> , 2012, 61, 237-242.	1.9	69
76	Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 61, 854-855.	1.9	152
77	Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study. <i>European Urology</i> , 2012, 61, 810-817.	1.9	163
78	Subclassification of pT3 Urothelial Carcinoma of the Renal Pelvicalyceal System is Associated With Recurrence-Free and Cancer-Specific Survival: Proposal for a Revision of the Current TNM Classification. <i>European Urology</i> , 2012, 62, 224-231.	1.9	44
79	Extended Pelvic Lymph Node Dissection Does Not Affect Erectile Function Recovery in Patients Treated with Bilateral Nerve-Sparing Radical Prostatectomy. <i>Journal of Sexual Medicine</i> , 2012, 9, 2187-2194.	0.6	17
80	A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. <i>BJU International</i> , 2012, 109, 1627-1635.	2.5	59
81	Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis. <i>BJU International</i> , 2012, 110, E183-90.	2.5	19
82	Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients. <i>BJU International</i> , 2012, 110, 1714-1720.	2.5	12
83	Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions. <i>Journal of Urology</i> , 2011, 185, 2119-2125.	0.4	136
84	Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. <i>BJU International</i> , 2011, 107, 1668-1675.	2.5	89
85	Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. <i>BJU International</i> , 2011, 107, 765-770.	2.5	120
86	Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score. <i>BJU International</i> , 2011, 107, 1562-1569.	2.5	36
87	Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. <i>BJU International</i> , 2011, 107, 1755-1761.	2.5	105
88	Older patients suffer from adverse histopathological features after radical cystectomy. <i>International Journal of Urology</i> , 2011, 18, 576-584.	1.0	15
89	Critical Assessment of Preoperative Urinary Prostate Cancer Antigen 3 on the Accuracy of Prostate Cancer Staging. <i>European Urology</i> , 2011, 59, 96-105.	1.9	127
90	Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer. <i>European Urology</i> , 2011, 60, 1045-1054.	1.9	148

#	ARTICLE	IF	CITATIONS
91	Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 811-819.	2.5	25
92	Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. <i>World Journal of Urology</i> , 2011, 29, 473-480.	2.2	62
93	Reply to Juan Morote's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>Eur Urol</i> 2009;56:659-68. <i>European Urology</i> , 2010, 57, e2-e3.	1.9	6
94	Head-to-Head Comparison of the Three Most Commonly Used Preoperative Models for Prediction of Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2010, 57, 562-568.	1.9	69
95	External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome. <i>European Urology</i> , 2010, 58, 727-732.	1.9	96
96	Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature. <i>European Urology</i> , 2010, 58, 851-864.	1.9	96
97	External Validation of a Preoperative Nomogram for Prediction of the Risk of Recurrence After Radical Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 788-792.	0.8	9
98	Unilateral Prostate Cancer Cannot be Accurately Predicted in Low-Risk Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 784-787.	0.8	24
99	The presence of prostate cancer on saturation biopsy can be accurately predicted. <i>BJU International</i> , 2010, 105, 636-641.	2.5	19
100	Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer. <i>BJU International</i> , 2010, 105, 818-823.	2.5	6
101	[F18]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study. <i>European Journal of Cancer</i> , 2010, 46, 449-455.	2.8	39
102	Biochemical Recurrence After Radical Prostatectomy: Multiplicative Interaction Between Surgical Margin Status and Pathological Stage. <i>Journal of Urology</i> , 2010, 184, 1341-1346.	0.4	84
103	From Gene to Clinic: TMA-Based Clinical Validation of Molecular Markers in Prostate Cancer. <i>Methods in Molecular Biology</i> , 2010, 664, 177-189.	0.9	9
104	Circulating Prostate Tumor Cells Detected by Reverse Transcription-PCR in Men with Localized or Castration-Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival. <i>Clinical Chemistry</i> , 2009, 55, 765-773.	3.2	122
105	Assessment of Pathological Prostate Cancer Characteristics in Men with Favorable Biopsy Features on Predominantly Sextant Biopsy. <i>European Urology</i> , 2009, 55, 617-628.	1.9	25
106	Molecular Cancer Phenotype in Normal Prostate Tissue. <i>European Urology</i> , 2009, 55, 885-891.	1.9	23
107	Prevalence of a Tertiary Gleason Grade and Its Impact on Adverse Histopathologic Parameters in a Contemporary Radical Prostatectomy Series. <i>European Urology</i> , 2009, 55, 394-403.	1.9	35
108	Risk-Adjusted Hazard Rates of Biochemical Recurrence for Prostate Cancer Patients after Radical Prostatectomy. <i>European Urology</i> , 2009, 55, 412-421.	1.9	18

#	ARTICLE	IF	CITATIONS
109	Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>European Urology</i> , 2009, 56, 659-668.	1.9	161
110	Prediction of sexual function after radical prostatectomy. <i>Cancer</i> , 2009, 115, 3150-3159.	4.1	33
111	Effect of Body Mass Index on Histopathologic Parameters: Results of Large European Contemporary Consecutive Open Radical Prostatectomy Series. <i>Urology</i> , 2009, 73, 615-619.	1.0	30
112	Predictive Value of Prostate-specific Antigen Expression in Prostate Cancer: A Tissue Microarray Study. <i>Urology</i> , 2009, 74, 1169-1173.	1.0	18
113	Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. <i>Thrombosis and Haemostasis</i> , 2009, 101, 1147-1155.	3.4	67
114	Nomogram Predicting the Probability of Early Recurrence After Radical Prostatectomy for Prostate Cancer. <i>Journal of Urology</i> , 2009, 181, 601-608.	0.4	129
115	Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. <i>Cancer</i> , 2008, 113, 701-709.	4.1	86
116	Currently used criteria for active surveillance in men with low-risk prostate cancer. <i>Cancer</i> , 2008, 113, 2068-2072.	4.1	96
117	Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. <i>Cancer</i> , 2008, 113, 2695-2703.	4.1	32
118	A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. <i>BJU International</i> , 2008, 101, 556-560.	2.5	24
119	Comparison of stage migration patterns between Europe and the USA: an analysis of 11,350 men treated with radical prostatectomy for prostate cancer. <i>BJU International</i> , 2008, 101, 1513-1518.	2.5	134
120	Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. <i>BJU International</i> , 2008, 102, 253-258.	2.5	38
121	Marked Gene Transcript Level Alterations Occur Early During Radical Prostatectomy. <i>European Urology</i> , 2008, 53, 333-346.	1.9	40
122	Contemporary Prostate Cancer Prevalence among T1c Biopsy-Referred Men with a Prostate-Specific Antigen Level \geq 4.0 ng per Milliliter. <i>European Urology</i> , 2008, 53, 750-757.	1.9	24
123	Evaluation of Prostate Cancer Detection with Ultrasound Real-Time Elastography: A Comparison with Step Section Pathological Analysis after Radical Prostatectomy. <i>European Urology</i> , 2008, 54, 1354-1362.	1.9	226
124	Editorial Comment on: Preliminary Results of a Novel Method to Estimate the Probability of Prostate Cancer in Men with Elevated Serum PSA Values. <i>European Urology</i> , 2008, 54, 702.	1.9	0
125	Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer. <i>European Urology</i> , 2008, 54, 794-804.	1.9	61
126	Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis. <i>European Urology</i> , 2008, 54, 1373-1378.	1.9	91

#	ARTICLE	IF	CITATIONS
127	NERVE-SPARING RADICAL PROSTATECTOMY DOES NOT UNDERMINE THE RATE OF BIOCHEMICAL RECURRENCE IN CAREFULLY SELECTED PATIENTS WITH PATHOLOGICALLY CONFIRMED EXTRACAPSULAR EXTENSION. Journal of Urology, 2008, 179, 646-647.	0.4	0
128	LONG TERM OUTCOME OF PATIENTS WITH POSITIVE LYMPH NODES DURING RADICAL PROSTATECTOMY: SURVIVAL BENEFIT OF PATIENTS WITH COMPLETED VS. ABANDONED SURGERY. Journal of Urology, 2008, 179, 252-252.	0.4	0
129	[18F]FLUOROCHOLINE COMBINED IN-LINE PET-CT SCAN FOR DETECTION OF LYMPH-NODE METASTASIS PRIOR TO RADICAL PROSTATECTOMY: RESULTS FROM A PROSPECTIVE HISTOLOGY BASED STUDY. Journal of Urology, 2008, 179, 49-49.	0.4	1
130	Biopsies Performed at Tertiary Care Centers are Superior to Referral Biopsies in Predicting Pathologic Gleason Sum. Journal of Endourology, 2008, 22, 533-538.	2.1	7
131	Critical Assessment of Ideal Nodal Yield at Pelvic Lymphadenectomy to Accurately Diagnose Prostate Cancer Nodal Metastasis in Patients Undergoing Radical Retropubic Prostatectomy. Urology, 2007, 69, 147-151.	1.0	156
132	Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy. European Journal of Cancer, 2007, 43, 375-382.	2.8	20
133	Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. European Journal of Cancer, 2007, 43, 536-543.	2.8	77
134	Prostate volume and adverse prostate cancer features: Fact not artifact. European Journal of Cancer, 2007, 43, 2669-2677.	2.8	82
135	Development and External Validation of an Extended Repeat Biopsy Nomogram. Journal of Urology, 2007, 177, 510-515.	0.4	75
136	Plasma tissue factor antigen in localized prostate cancer: Distribution, clinical significance and correlation with haemostatic activation markers. Thrombosis and Haemostasis, 2007, 97, 464-470.	3.4	35
137	Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. International Journal of Cancer, 2007, 120, 1465-1471.	5.1	54
138	Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. International Journal of Cancer, 2007, 121, 791-795.	5.1	44
139	A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU International, 2007, 99, 794-800.	2.5	111
140	Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer. BJU International, 2007, 99, 1404-1408.	2.5	16
141	Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU International, 2007, 100, 37-41.	2.5	19
142	Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. BJU International, 2007, 100, 528-532.	2.5	33
143	Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy. BJU International, 2007, 100, 1249-1253.	2.5	16
144	A Nomogram for Staging of Exclusive Nonobturator Lymph Node Metastases in Men with Localized Prostate Cancer. European Urology, 2007, 51, 112-120.	1.9	66

#	ARTICLE	IF	CITATIONS
145	Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy. <i>European Urology</i> , 2007, 51, 949-955.	1.9	23
146	Initial Biopsy Outcome Prediction—Head-to-Head Comparison of a Logistic Regression-Based Nomogram versus Artificial Neural Network. <i>European Urology</i> , 2007, 51, 1236-1243.	1.9	79
147	Development and External Validation of an Extended 10-Core Biopsy Nomogram. <i>European Urology</i> , 2007, 52, 436-445.	1.9	114
148	Reply to Carsten Stephan et al's Letter to the Editor re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial Biopsy Outcome Prediction—Head-to-Head Comparison of a Logistic Regression-Based Nomogram versus Artificial Neural Network. <i>Eur Urol</i> 2007;51:1236-43. <i>European Urology</i> , 2007, 51, 1448.	1.9	2
149	Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20ng/mL. <i>European Urology</i> , 2007, 52, 1374-1380.	1.9	16
150	Percentage of Positive Biopsy Cores Can Improve the Ability to Predict Lymph Node Invasion in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2007, 51, 1573-1581.	1.9	84
151	Systematic Assessment of the Ability of the Number and Percentage of Positive Biopsy Cores to Predict Pathologic Stage and Biochemical Recurrence after Radical Prostatectomy. <i>European Urology</i> , 2007, 52, 733-745.	1.9	35
152	Prostate-Specific Antigen Improves the Ability of Clinical Stage and Biopsy Gleason Sum to Predict the Pathologic Stage at Radical Prostatectomy in the New Millennium. <i>European Urology</i> , 2007, 52, 1067-1075.	1.9	19
153	Reply to Ian Beckley and Masood A. Khan's Letter to the Editor re: Felix K.-H. Chun, Thomas Steuber, Andreas Erbersdobler, et al. Development and Internal Validation of a Nomogram Predicting the Probability of Prostate Cancer Gleason Sum Upgrading Between Biopsy and Radical Prostatectomy Pathology. <i>Eur Urol</i> 2006;49:820-26. <i>European Urology</i> , 2007, 52, 1271.	1.9	0
154	Role of nomograms for prostate cancer in 2007. <i>World Journal of Urology</i> , 2007, 25, 131-142.	2.2	48
155	Management of erectile dysfunction after radical prostatectomy in 2007. <i>World Journal of Urology</i> , 2007, 25, 143-148.	2.2	37
156	A Comparative Review of Apomorphine Formulations for Erectile Dysfunction. <i>Drugs and Aging</i> , 2006, 23, 309-319.	2.7	5
157	25-Year Prostate Cancer Control and Survival Outcomes: A 40-Year Radical Prostatectomy Single Institution Series. <i>Journal of Urology</i> , 2006, 176, 569-574.	0.4	119
158	Validation of a Nomogram for Prediction of Side Specific Extracapsular Extension at Radical Prostatectomy. <i>Journal of Urology</i> , 2006, 175, 939-944.	0.4	163
159	Development and internal validation of preoperative transition zone prostate cancer nomogram. <i>Urology</i> , 2006, 68, 1295-1300.	1.0	16
160	Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer. <i>BJU International</i> , 2006, 98, 50-53.	2.5	11
161	Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. <i>BJU International</i> , 2006, 98, 329-334.	2.5	126
162	Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. <i>BJU International</i> , 2006, 98, 788-793.	2.5	162

#	ARTICLE	IF	CITATIONS
163	Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU International, 2006, 98, 544-548.	2.5	104
164	Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. BJU International, 2006, 98, 1204-1209.	2.5	62
165	Anatomic radical retropubic prostatectomyâ€™long-term recurrence-free survival rates for localized prostate cancer. World Journal of Urology, 2006, 24, 273-280.	2.2	134
166	Development and Internal Validation of a Nomogram Predicting the Probability of Prostate Cancer Gleason Sum Upgrading Between Biopsy and Radical Prostatectomy Pathology. European Urology, 2006, 49, 820-826.	1.9	188
167	The 2002 AJCC pT2 Substages Confer No Prognostic Information on the Rate of Biochemical Recurrence After Radical Prostatectomy. European Urology, 2006, 49, 273-279.	1.9	45
168	Validation of a Nomogram Predicting the Probability of Lymph Node Invasion among Patients Undergoing Radical Prostatectomy and an Extended Pelvic Lymphadenectomy. European Urology, 2006, 49, 1019-1027.	1.9	215
169	Tumor Size Improves the Accuracy of TNM Predictions in Patients with Renal Cancer. European Urology, 2006, 50, 521-529.	1.9	60
170	Frozen Section for the Management of Intraoperatively Detected Palpable Tumor Lesions During Nerve-Sparing Scheduled Radical Prostatectomy. European Urology, 2006, 49, 1011-1018.	1.9	67
171	High Radical Prostatectomy Surgical Volume is Related to Lower Radical Prostatectomy Total Hospital Charges. European Urology, 2006, 50, 58-63.	1.9	23
172	High Incidence of Prostate Cancer Detected by Saturation Biopsy after Previous Negative Biopsy Series. European Urology, 2006, 50, 498-505.	1.9	178
173	Outcomes Research: A Methodologic Review. European Urology, 2006, 50, 218-224.	1.9	19
174	Prostate Cancer Nomograms: An Update. European Urology, 2006, 50, 914-926.	1.9	89
175	Complications and Other Surgical Outcomes Associated with Extended Pelvic Lymphadenectomy in Men with Localized Prostate Cancer. European Urology, 2006, 50, 1006-1013.	1.9	341
176	Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. International Journal of Cancer, 2006, 118, 1234-1240.	5.1	48
177	A MULTICENTER CLINICAL TRIAL ON THE USE OF (â€“5, â€“7) PRO PROSTATE SPECIFIC ANTIGEN. Journal of Urology, 2005, 174, 2150-2153.	0.4	41